GlassScriptPhysician profile
Christopher Chase Surek
NPI 1114264637
$1,024,534.70
in general payments reported to CMS, 2019-2025
26 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $196K · 2021: $184K · 2022: $243K · 2023: $71K · 2024: $75K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $144K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Travel and Lodging: $8,357 · Food and Beverage: $5,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $144,025.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,575.00 |
| Travel and Lodging | $8,356.64 |
| Food and Beverage | $5,308.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $638,188.38 | 2019-2025 | Dysport |
| Allergan, INC. | $263,985.54 | 2019-2022 | |
| Abbvie INC. | $101,610.33 | 2022-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Ipsen Innovation | $12,325.00 | 2019 | |
| Sientra, INC. | $4,059.37 | 2019-2022 | |
| Tepha INC | $1,340.27 | 2019-2020 | |
| Davol INC. | $525.22 | 2022-2024 | Phasix Mesh |
| Motiva USA, LLC | $353.73 | 2024-2025 | |
| Mentor Worldwide LLC | $318.35 | 2019-2025 | Mentor Cpx 2 Breast Tissue Expander |
| Tela Bio, INC. | $290.69 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Bard Peripheral Vascular, INC. | $241.34 | 2021 | |
| Lilly USA, LLC | $184.44 | 2021-2022 | |
| Integra Lifesciences Corporation | $175.33 | 2023 | Durasorb Monofilament Mesh |
| Musculoskeletal Transplant Foundation INC. | $138.90 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $122.21 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.73 | 2023 | |
| Celgene Corporation | $110.77 | 2019 | |
| Stemline Therapeutics INC. | $104.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $100.31 | 2019 | |
| Merz North America, INC. | $75.66 | 2023 | Xeomin |
| E.R. Squibb & Sons, L.L.C. | $68.26 | 2023 | |
| Baudax Bio INC. | $32.28 | 2020 | |
| Almirall LLC | $27.88 | 2020 | |
| Mayne Pharma Commercial LLC | $15.48 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.77 | 2019 | |
| Arteriocyte Medical Systems, INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Surek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.